文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

基于BLAST风险分层的异基因移植对CMML生存影响

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.
PubMed 文献 · Am J Hematol · 2026-07-24

该回顾性研究纳入775例Mayo Clinic连续CMML患者,按BLAST/BLAST-Mol风险分层比较异基因移植(ASCT)与未移植的生存差异。中位随访77个月,151例(20%)接受ASCT;ASCT组总生存(OS)显著优于非ASCT组(中位77 vs. 28个月,p<0.01),且在高、中风险组调整后仍显著。

要点

  • ASCT组中位OS 77个月,非ASCT组28个月(p<0.01)
  • BLAST高风险组ASCT中位OS 50 vs. 14个月(p<0.01)
  • BLAST中风险组ASCT中位OS 81 vs. 28个月(p<0.01)

核心结论

  • ASCT可改善CMML患者总生存,尤其BLAST/BLAST-Mol高、中风险组获益显著。

研究设计与样本

  • Mayo Clinic连续CMML患者回顾性队列,n=775,68%男性,中位年龄71岁。
  • 中位随访77个月,151例(20%)接受ASCT。

主要发现

  • ASCT组中位OS 77个月,非ASCT组28个月(p<0.01)。
  • BLAST高风险组ASCT中位OS 50 vs. 14个月(p<0.01)。
  • BLAST中风险组ASCT中位OS 81 vs. 28个月(p<0.01)。
  • BLAST低风险组ASCT中位OS 111 vs. 65个月(p=0.04)。
  • BLAST-Mol分层高、中、低风险组p值分别为<0.01、<0.01、0.08。

临床怎么用

  • BLAST/BLAST-Mol高、中风险CMML患者应尽早考虑ASCT。
  • ASCT宜在疾病转化前进行,可不依赖遗传学特征选择。

局限性

  • 回顾性单中心研究,ASCT组仅占20%,选择偏倚可能存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST-Mol) differentiate low, intermediate, and high-risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients (n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST-Mol risk categories. At a median follow-up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non-ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non-ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high-risk (median 50 vs. 14 months; p < 0.01), intermediate-risk (81 vs. 28 months; p < 0.01), and low-risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST-Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time-dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST-Mol high- and intermediate-risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST-Mol high- and intermediate-risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Alsugair A, Fathima S, Alhousani MM, et al. Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients. Am J Hematol. 2026. PMID: 42499183. doi:10.1002/ajh.70453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。